Apixaban is a highly selective, oral Factor Xa inhibitor used to prevent and treat thromboembolic disorders. It is widely prescribed for stroke prevention in non-valvular atrial fibrillation and for managing deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban offers a predictable pharmacological profile with a lower bleeding risk compared to traditional anticoagulants. As a cornerstone of NOAC (novel oral anticoagulant) therapy, Apixaban continues to gain global acceptance for its convenience and efficacy.

Explore Royal Pharma as your potential partner for Apixaban API.